Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Lung Cancer, Metastatic Cancer
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00892801
- Testing
- RAD001, whole-brain radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Neoplasms, Lung Cancer, Nonsmall Cell
A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
This study aims to verify the efficacy and safety of osimertinib in patients with EGFR-sensitive mutation non-small cell lung cancer who progressed after adjuvant targeted therapy following radical surgery.
- Trial name
- NCT06530719
- Testing
- Osimertinib mesylate
- Volunteers
- 54 people
- Sponsor
- Jin Ying
Non-small Cell Lung Cancer Stage III, Radiotherapy Side Effect
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Aim To test if proton therapy can improve survival compared to photon therapy in patients with locally advanced NSCLC who are not candidates for standard definitive chemo-radiotherapy.
- Conditions
- Non-small Cell Lung Cancer Stage III, Radiotherapy Side Effect, Frailty
- Trial name
- HERAN2 (NCT05548504)
- Testing
- Photon, Proton
- Volunteers
- 182 people
- Sponsor
- Odense University Hospital
Lung Cancer, Metastatic Cancer
Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NRR (NCT00280748)
- Testing
- pemetrexed disodium, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic NSCLC - Non-Small Cell Lung Cancer
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes.
- Trial name
- NCT07149649
- Testing
- Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose
- Where
- 9 sites in Switzerland
- Volunteers
- 230 people
- Sponsor
- Swiss Cancer Institute
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
This randomized phase II trial is studying carboplatin, paclitaxel, and vorinostat to see how well they work compared with carboplatin, paclitaxel, and a placebo in treating patients with stage III or stage IV non-small cell lung…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00481078
- Testing
- vorinostat, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114192
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Virginia
Nonsquamous Non-Small Cell Lung Cancer
A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
This prospective, single-center, randomized, controlled study will evaluate the efficacy and safety of sintilimab compared with docetaxel or pemetrexed as second-line treatment for patients with stage IV nonsquamous non-small…
- Trial name
- NCT03830411
- Testing
- Sintilimab, Docetaxel, Pemetrexed
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Xin-Hua Xu
Lung Cancer
Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well…
- Trial name
- NCT00534209
- Testing
- Allogeneic B7.1/HLA-A1
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Lung Cancer
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248495
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute
Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.
- Conditions
- Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT01822496
- Testing
- Radiation Therapy, Carboplatin, Cisplatin
- Where
- 174 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Stage IV Non-Small Cell Lung Cancer
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
The goal of this clinical trial is to determine if low single palliative dose radiation to the lung cancer will improve your immune response against the tumor and if sequential treatment with pembrolizumab (the study drug) would…
- Trial name
- NCT02658097
- Testing
- Pembrolizumab, Single Fraction Radiation Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Patients with advanced or metastatic (stage IIIB-IV) non small cell lung cancer who have not received prior chemotherapy will be treated with erlotinib 150 mg once a day and sorafenib 400 mg twice a day.
- Trial name
- NCT00722969
- Testing
- sorafenib + erlotinib
- Where
- 4 sites in Netherlands
- Volunteers
- 48 people
- Sponsor
- Universitair Ziekenhuis Brussel
Lung Cancer
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, carboplatin, and paclitaxel and work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00728845
- Testing
- bevacizumab, carboplatin, hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer(NSCLC)
Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca
To compare clinical response (complete response and partial response) by RECIST) rates by RECIST between erlotinib monotherapy and docetaxel plus cisplatin chemotherapy
- Trial name
- Oncology (NCT02036359)
- Testing
- erlotinib, docetaxel
- Where
- Taiwan
- Volunteers
- 76 people
- Sponsor
- National Taiwan University Hospital
Non Small Cell Lung Cancer, Small Cell Lung Cancer
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients…
- Trial name
- NCT07253142
- Testing
- HLX43 dose 1, HLX43 dose 2
- Where
- 10 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Henlius Biotech
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Carcinoma, Non-small-cell Lung
Study of Tarceva and Targretin in Stage I-II Lung Cancer
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor.
- Trial name
- NCT00125372
- Testing
- erlotinib (Tarceva) and bexarotene (Targretin)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant
Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC
In this study, a pragmatic, open labelled, multi-center randomized controlled trial will be conducted. The study population are stage II and IIIA NSCLC patients undergoing R0 resection and will be scheduled for adjuvant…
- Trial name
- NCT03712969
- Testing
- Shenlingcao Oral Liquid
- Where
- China
- Volunteers
- 527 people
- Sponsor
- West China Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.